Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efinaconazole - Bausch Health Companies/Kaken Pharmaceutical

Drug Profile

Efinaconazole - Bausch Health Companies/Kaken Pharmaceutical

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Bausch Health Companies; Dong-A ST; Kaken Pharmaceutical; Main Life Corporation; Tai Tien Pharmaceuticals
  • Class Antifungals; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 31 Oct 2019 Registered for Onychomycosis in Hong Kong (Topical)
  • 31 Oct 2019 Main Life Corporation plans to launch efinaconazole for Onychomycosis in Hong Kong
  • 13 Feb 2019 Perrigo settles patent litigation of ANDA submission for efinaconazole topical solution 10% in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top